姓  名: 吕赫喆
学  科: 生理学与病理生理学
电话/传真: +86-10-6480 7150 / 
电子邮件: Hezhe@ioz.ac.cn
通讯地址: 北京市朝阳区大屯路甲3号院
中国科学院干细胞与再生医学创新研究院大楼 421房间 中国科学院动物研究所器官再生与智造全国重点实验室 100101
更多信息: 细胞异质性与命运决定研究组     

简历介绍:

  吕赫喆, 中国科学院动物研究所膜生物学国家重点实验室研究员。2011年于北京师范大学获得细胞生物学博士学位,后于美国宾夕法尼亚大学、加拿大Lunenfeld-Tanenbaum研究所从事肿瘤异质性方面的博士后研究。2020年7月加入中国科学院动物研究所成立细胞异质性与命运决定研究组。研究内容围绕膜信号在引发重大疾病的罕见细胞中的作用,利用单细胞分析技术和DNA条形码技术研究细胞命运轨迹,并应用高通量药物筛选技术筛选抗肿瘤先导化合物。取得了系列研究成果,分别发表于Nature、Cell Reports、Development Cell等杂志。目前任International journal of biological sciences、Journal of Genetics and Genomics等杂志特邀审稿人。
  现有博士研究生2名、硕士研究生2名、联合培养研究生1名。

研究领域:

  实验室主要聚焦细胞异质性在疾病发生、发展中的作用,结合细胞生物学和生物信息学等手段,研究(1)探寻罕见耐药肿瘤细胞并设计靶点药物;(2)研究细胞发生致癌基因突变后的命运轨迹;(3)研究T细胞异质性,筛选刺激T细胞向肿瘤侵袭的小分子药物。

社会任职:

获奖及荣誉:

承担科研项目情况:

代表论著:

  1.  YIifang Chen, et.al. Hezhe Lu#, Yong Zhao# (2026) IL-33/TGF-β/IL-4-induced bone marrow-derived DC9 subset promotes Th9 differentiation and allergic airway inflammation. Cell Reports. 4;45(6):117519.
  2.  Yuetong Zhang, et.al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell. 12;44(1):77-93
  3.   Haifeng Lin, et.al. Hezhe Lu# (2025) CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer. Signal Transduction and Targeted Therapy. 10:335.
  4. Miao Wang, et.al. Hezhe Lu#, Xiaowei Xu#, Yusheng Cong# (2025) PTRF Confers Melanoma-Acquired Drug Resistance Through the Upregulation of EGFR. Cell Prolif. Jul 31:e70086
  5. Maoduo Zhang, et.al. Hezhe Lu# (2025) Association between treatment-related adverse events and clinical outcomes in NSCLC patients receiving neoadjuvant immunochemotherapy: a retrospective study. Curr Med Res Opin. 41(10):1933-1944
  6. Aicun Li, et.al. (2025) Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. Dev. Cell. 21;60(14):1974-1990
  7. Mingjie Ma, et.al. (2025) Symbiotic solutions for colony nutrition: Conserved nitrogen recycling within the bacterial pouch of Tetraponera ants. PNAS. 4;122(44)
  8. Hui husan Yang, et.al. Hezhe Lu# (2024) Tacrolimus Related Acute Pancreatitis: An Observational, Retrospective, Pharmacovigilance Study. Clinical Therapeutics. 46(9988)
  9. Yifang Chen, Chenxu Zhao, Han Guo, et.al., Hezhe Lu#, Lianfeng Zhang# and Yong Zhao# (2023) Wip1 inhibits neutrophil extracellular traps to promote abscess formation in mice by directly dephos. Cell Mol Immunol. 20(8):941-954
  10. Lei Guo*; Weiping Zhou*; Ziwei Xu*; Xiaoqing Cao; Shiya Wan; Ying Yi Zhang#; Jie Zhang#; Hezhe Lu#; (2023) Identification of IRAK1BP1 as a candidate prognostic factor in lung adenocarcinoma, Frontiers in Oncology, 13(1132811)
  11. Zizhu Li, Ying Yi Zhang, Haomiao Zhang, Hezhe Lu# (2022) Asymmetric Cell Division and Tumor Heterogeneity. Frontiers in Cell and Developmental Biology 10:938685
  12. Maoduo Zhang, Ying Yi Zhang, Yongze Chen, Hezhe Lu# (2021) TGF-β Signaling and Resistance to Cancer Therapy. Frontiers in Cell and Developmental Biology 9:786728.
  13. Hezhe Lu*, Shujing Liu*, Gao Zhang*, Bin Wu, et. al. (2017) PAK signalling drives   acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550:133-136. (* Equal Contribution)
  14. Hezhe Lu*, Shujing Liu*, Gao Zhang, Yi Hu, et. al. (2016) Oncogenica BRAF-induced invadopodia formation and melanoma invasion. Cell Reports. 15(9): 2012–2024. (* Equal Contribution)
  15. Hezhe Lu, Jianglan Liu, Shujing Liu, et. al. (2013) Exo70 isoform switching upon Epithelial-Mesenchymal transition mediates cancer cell invasion. Dev Cell. 27(5): 560-573
  16. Hezhe Lu, Ellen Fan, Suozhu Sun, et. al. (2009) Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J Cell Biochem 106 (4): 738-744.

写给考生的话:

关于我们
联系我们
地  址:北京市朝阳区北辰西路1号院5号
邮  编:100101
电子邮件:ioz@ioz.ac.cn
电  话:+86-10-64807098
传  真:+86-10-64807099
友情链接